Xencor (XNCR) Revenue & Revenue Breakdown
Xencor Revenue Highlights
Latest Revenue (Y)
$168.34M
Latest Revenue (Q)
$16.96M
Main Segment (Y)
Milestone
Main Geography (Y)
U
Xencor Revenue by Period
Xencor Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $168.34M | 2.28% |
| 2022-12-31 | $164.58M | -40.18% |
| 2021-12-31 | $275.11M | 124.23% |
| 2020-12-31 | $122.69M | -21.70% |
| 2019-12-31 | $156.70M | 285.93% |
| 2018-12-31 | $40.60M | 13.70% |
| 2017-12-31 | $35.71M | -59.20% |
| 2016-12-31 | $87.52M | 215.25% |
| 2015-12-31 | $27.76M | 191.62% |
| 2014-12-31 | $9.52M | -6.41% |
| 2013-12-31 | $10.17M | 6.80% |
| 2012-12-31 | $9.52M | 39.06% |
| 2011-12-31 | $6.85M | - |
Xencor generated $168.34M in revenue during NA 2023, up 2.28% compared to the previous quarter, and up 414.59% compared to the same period a year ago.
Xencor Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $16.96M | 32.45% |
| 2024-03-31 | $12.80M | -71.35% |
| 2023-12-31 | $44.69M | -24.47% |
| 2023-09-30 | $59.16M | 29.97% |
| 2023-06-30 | $45.52M | 140.07% |
| 2023-03-31 | $18.96M | -12.25% |
| 2022-12-31 | $21.61M | -20.84% |
| 2022-09-30 | $27.30M | -9.53% |
| 2022-06-30 | $30.18M | -64.71% |
| 2022-03-31 | $85.50M | -44.49% |
| 2021-12-31 | $154.02M | 682.48% |
| 2021-09-30 | $19.68M | -70.82% |
| 2021-06-30 | $67.45M | 98.58% |
| 2021-03-31 | $33.97M | -18.85% |
| 2020-12-31 | $41.85M | 18.35% |
| 2020-09-30 | $35.37M | 170.20% |
| 2020-06-30 | $13.09M | -59.58% |
| 2020-03-31 | $32.38M | 821.08% |
| 2019-12-31 | $3.52M | -83.84% |
| 2019-09-30 | $21.76M | 11.68% |
| 2019-06-30 | $19.48M | -82.59% |
| 2019-03-31 | $111.94M | 868.00% |
| 2018-12-31 | $11.56M | -60.18% |
| 2018-09-30 | $29.04M | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $10.94M | 54.32% |
| 2017-09-30 | $7.09M | -46.85% |
| 2017-06-30 | $13.34M | 207.37% |
| 2017-03-31 | $4.34M | -32.61% |
| 2016-12-31 | $6.44M | -17.66% |
| 2016-09-30 | $7.82M | -88.15% |
| 2016-06-30 | $66.01M | 810.19% |
| 2016-03-31 | $7.25M | -66.66% |
| 2015-12-31 | $21.75M | 521.01% |
| 2015-09-30 | $3.50M | 245.46% |
| 2015-06-30 | $1.01M | -31.99% |
| 2015-03-31 | $1.49M | -73.68% |
| 2014-12-31 | $5.66M | 567.92% |
| 2014-09-30 | $848.00K | 2.91% |
| 2014-06-30 | $824.00K | -62.27% |
| 2014-03-31 | $2.18M | 25.23% |
| 2013-12-31 | $1.74M | -44.85% |
| 2013-09-30 | $3.16M | -19.36% |
| 2013-06-30 | $3.92M | 191.52% |
| 2013-03-31 | $1.34M | -44.54% |
| 2012-12-31 | $2.42M | 53.87% |
| 2012-09-30 | $1.58M | - |
Xencor generated $16.96M in revenue during Q2 2024, up 32.45% compared to the previous quarter, and up 89.44% compared to the same period a year ago.
Xencor Revenue Breakdown
Xencor Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License | - | - | $50.20M | $112.20M | - |
| Royalty | $49.50M | $152.10M | $17.80M | $5.00M | - |
| Research collaboration | $30.30M | $7.00M | $93.00M | - | - |
| Milestone | $88.50M | $5.50M | $21.00M | $50.20M | $23.20M |
| Royalties | - | - | $80.30M | - | - |
| Licensing | - | - | $80.80M | - | - |
| Collaboration | - | - | - | $4.50M | $16.30M |
Xencor's latest annual revenue breakdown by segment (product or service), as of Dec 23: Milestone (52.58%), Royalty (29.41%), and Research collaboration (18.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | - | $7.90M | $14.50M | $13.30M | $13.80M | $16.20M | $13.40M | $7.30M | $6.70M | $6.10M | $4.50M | $3.80M | $3.30M | $2.50M | $1.40M | $1.10M | - | - | - | - |
| Research collaboration | - | $9.20M | $-1.30M | $22.20M | $200.00K | $4.90M | $100.00K | $200.00K | $1.80M | $13.30M | $6.30M | - | - | - | - | - | - | - | - | - |
| Non-cash Royalty | $12.30M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Milestone | $500.00K | $27.50M | $46.00M | $10.00M | $5.00M | $500.00K | - | - | $5.00M | $7.00M | - | $1.50M | $12.50M | $12.40M | $25.00M | $300.00K | $12.50M | $-100.00K | $19.30M | $4.00M |
| Royalties | - | - | - | - | - | - | $27.20M | $30.00M | $78.70M | $52.90M | - | - | - | - | - | - | - | - | - | - |
| Collaboration | - | - | - | - | - | - | - | - | - | - | - | $58.60M | $14.80M | $1.30M | $900.00K | $1.50M | $1.00M | $1.10M | $600.00K | $14.40M |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | $22.10M | $5.00M | $7.50M | $15.60M | - | $500.00K | $111.60M |
Xencor's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Non-cash Royalty (96.09%), and Milestone (3.91%).
Xencor Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|
| Non United States | $58.60M | $14.00M | - |
| U | $64.10M | $142.70M | $40.60M |
Xencor's latest annual revenue breakdown by geography, as of Dec 20: U (52.24%), and Non United States (47.76%).
Xencor Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| XNCR | Xencor | $168.34M | $16.96M |
| STRO | Sutro Biopharma | $153.73M | $13.01M |
| ACLX | Arcellx | $110.32M | $27.38M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MRUS | Merus | $43.95M | $7.33M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| FIXX | Q32 Bio | $1.16M | - |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| DICE | DICE Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| ERAS | Erasca | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
XNCR Revenue FAQ
What is Xencor’s yearly revenue?
Xencor's yearly revenue for 2023 was $168.34M, representing an increase of 2.28% compared to 2022. The company's yearly revenue for 2022 was $164.58M, representing a decrease of -40.18% compared to 2021. XNCR's yearly revenue for 2021 was $275.11M, representing an increase of 124.23% compared to 2020.
What is Xencor’s quarterly revenue?
Xencor's quarterly revenue for Q2 2024 was $16.96M, a 32.45% increase from the previous quarter (Q1 2024), and a -62.74% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $12.8M, a -71.35% decrease from the previous quarter (Q4 2023), and a -32.47% decrease year-over-year (Q1 2023). XNCR's quarterly revenue for Q4 2023 was $44.69M, a -24.47% decrease from the previous quarter (Q3 2023), and a 106.80% increase year-over-year (Q4 2022).
What is Xencor’s revenue growth rate?
Xencor's revenue growth rate for the last 3 years (2021-2023) was -38.81%, and for the last 5 years (2019-2023) was 7.43%.
What are Xencor’s revenue streams?
Xencor's revenue streams in c 23 are Royalty, Research collaboration, and Milestone. Royalty generated $49.5M in revenue, accounting 29.41% of the company's total revenue, down -67.46% year-over-year. Research collaboration generated $30.3M in revenue, accounting 18.00% of the company's total revenue, up 332.86% year-over-year. Milestone generated $88.5M in revenue, accounting 52.58% of the company's total revenue, up 1509.09% year-over-year.
What is Xencor’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Xencor was Milestone. This segment made a revenue of $88.5M, representing 52.58% of the company's total revenue.